Top 10 Contract Manufacturers for Generics (CDMOs) in Israel

Robert Gultig

5 January 2026

Top 10 Contract Manufacturers for Generics (CDMOs) in Israel

User avatar placeholder
Written by Robert Gultig

5 January 2026

Introduction:

The global market for generic pharmaceuticals continues to grow, with an increasing demand for cost-effective alternatives to brand-name medications. In Israel, contract manufacturing organizations (CDMOs) play a crucial role in the production of generic drugs. With a focus on quality, efficiency, and innovation, Israeli CDMOs have established themselves as key players in the industry. According to recent data, the generic drug market in Israel is valued at over $1 billion, with a significant portion of production being outsourced to contract manufacturers.

Top 10 Contract Manufacturers for Generics (CDMOs) in Israel:

1. Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. is the largest generic drug manufacturer in Israel, with a market share of over 60%. The company produces a wide range of generic medications and has a strong presence in both domestic and international markets.

2. Perrigo Company plc
Perrigo Company plc is another major player in the Israeli generic pharmaceutical industry, with a focus on over-the-counter medications. The company’s products are exported to numerous countries around the world, contributing to Israel’s status as a key exporter of generic drugs.

3. Taro Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries Ltd. specializes in dermatological and topical medications, with a strong reputation for quality and innovation. The company’s products are distributed globally, making it a significant player in the Israeli CDMO market.

4. Neopharm Group
Neopharm Group is a leading contract manufacturer for generic pharmaceuticals in Israel, with a diverse portfolio of products. The company’s state-of-the-art manufacturing facilities and stringent quality control measures have earned it a strong reputation in the industry.

5. Mylan N.V.
Mylan N.V. is a multinational pharmaceutical company that operates a manufacturing facility in Israel specializing in generic drugs. The company’s commitment to affordability and accessibility has made it a trusted partner for healthcare providers worldwide.

6. Ferring Pharmaceuticals
Ferring Pharmaceuticals is a global pharmaceutical company with a manufacturing presence in Israel. The company’s focus on specialty medications and innovative drug delivery systems has set it apart in the CDMO market.

7. Neurim Pharmaceuticals
Neurim Pharmaceuticals is a specialty pharmaceutical company based in Israel, focusing on the development of central nervous system medications. The company’s cutting-edge research and development capabilities have positioned it as a key player in the Israeli CDMO sector.

8. Intec Pharma Ltd.
Intec Pharma Ltd. is a biopharmaceutical company that specializes in the development of controlled-release medications. With a focus on improving patient compliance and outcomes, the company has established itself as a leader in the Israeli contract manufacturing industry.

9. Dexcel Pharma
Dexcel Pharma is a leading contract manufacturer of generic pharmaceuticals in Israel, with a strong focus on oral solid dosage forms. The company’s dedication to quality and efficiency has enabled it to compete effectively in the global market.

10. RedHill Biopharma
RedHill Biopharma is a specialty biopharmaceutical company based in Israel, with a focus on gastrointestinal and infectious diseases. The company’s innovative product portfolio and commitment to research and development make it a key player in the Israeli CDMO market.

Insights:

The Israeli contract manufacturing industry for generics is poised for continued growth in the coming years, driven by factors such as increasing demand for affordable medications, technological advancements in drug development, and a growing emphasis on quality and compliance. With a strong reputation for innovation and efficiency, Israeli CDMOs are well-positioned to capitalize on these trends and expand their presence in the global market. According to industry forecasts, the generic drug market in Israel is projected to grow by 5% annually, reaching a value of $1.5 billion by 2025. This presents significant opportunities for contract manufacturers in Israel to further solidify their position as key players in the industry.

Related Analysis: View Previous Industry Report

Author: Robert Gultig in conjunction with ESS Research Team

Robert Gultig is a veteran Managing Director and International Trade Consultant with over 20 years of experience in global trading and market research. Robert leverages his deep industry knowledge and strategic marketing background (BBA) to provide authoritative market insights in conjunction with the ESS Research Team. If you would like to contribute articles or insights, please join our team by emailing support@essfeed.com.
View Robert’s LinkedIn Profile →